99 related articles for article (PubMed ID: 26796597)
1. MDM2 gene amplification in esophageal carcinoma.
Michalk M; Meinrath J; Künstlinger H; Koitzsch U; Drebber U; Merkelbach-Bruse S; Bollschweiler E; Kloth M; Hartmann W; Hölscher A; Quaas A; Grimminger PP; Odenthal M
Oncol Rep; 2016 Apr; 35(4):2223-7. PubMed ID: 26796597
[TBL] [Abstract][Full Text] [Related]
2. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
3. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.
Tanière P; Martel-Planche G; Maurici D; Lombard-Bohas C; Scoazec JY; Montesano R; Berger F; Hainaut P
Am J Pathol; 2001 Jan; 158(1):33-40. PubMed ID: 11141476
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe.
Tanière P; Martel-Planche G; Saurin JC; Lombard-Bohas C; Berger F; Scoazec JY; Hainaut P
Br J Cancer; 2001 Sep; 85(5):721-6. PubMed ID: 11531258
[TBL] [Abstract][Full Text] [Related]
6. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers.
Forslund A; Zeng Z; Qin LX; Rosenberg S; Ndubuisi M; Pincas H; Gerald W; Notterman DA; Barany F; Paty PB
Mol Cancer Res; 2008 Feb; 6(2):205-11. PubMed ID: 18314481
[TBL] [Abstract][Full Text] [Related]
7. Association between positive murine double minute 2 expression and clinicopathological characteristics of esophageal squamous cell carcinoma: a meta-analysis.
Chen JY; Yang H; Wen J; Luo KJ; Liu QW; Lei JY; Zhen YZ; Fu JH
Dis Esophagus; 2016 Oct; 29(7):856-863. PubMed ID: 25873358
[TBL] [Abstract][Full Text] [Related]
8. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
9. Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
Renouf DJ; Zhai R; Sun B; Xu W; Cheung WY; Heist RS; Kulke MH; Cescon D; Asomaning K; Marshall AL; Li S; Christiani DC; Liu G
J Gastroenterol Hepatol; 2013 Sep; 28(9):1482-8. PubMed ID: 23735059
[TBL] [Abstract][Full Text] [Related]
10. Expression of Akt and Mdm2 in human esophageal squamous cell carcinoma.
Takahashi K; Miyashita M; Makino H; Akagi I; Orita H; Hagiwara N; Nomura T; Gabrielson EW; Tajiri T
Exp Mol Pathol; 2009 Aug; 87(1):42-7. PubMed ID: 19124015
[TBL] [Abstract][Full Text] [Related]
11. MDM2 is overexpressed and regulated by the eukaryotic translation initiation factor 4E (eIF4E) in human squamous cell carcinoma of esophagus.
Hsu HS; Chen HW; Kao CL; Wu ML; Li AF; Cheng TH
Ann Surg Oncol; 2011 May; 18(5):1469-77. PubMed ID: 21080085
[TBL] [Abstract][Full Text] [Related]
12. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
Patel H; Polanco-Echeverry G; Segditsas S; Volikos E; McCart A; Lai C; Guenther T; Zaitoun A; Sieber O; Ilyas M; Northover J; Silver A
Int J Cancer; 2007 Dec; 121(12):2668-73. PubMed ID: 17721920
[TBL] [Abstract][Full Text] [Related]
13. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
14. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
15. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract][Full Text] [Related]
16. Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma.
Morgan RJ; Newcomb PV; Hardwick RH; Alderson D
Eur J Surg Oncol; 1999 Aug; 25(4):364-7. PubMed ID: 10419705
[TBL] [Abstract][Full Text] [Related]
17. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Cescon DW; Bradbury PA; Asomaning K; Hopkins J; Zhai R; Zhou W; Wang Z; Kulke M; Su L; Ma C; Xu W; Marshall AL; Heist RS; Wain JC; Lynch TJ; Christiani DC; Liu G
Clin Cancer Res; 2009 May; 15(9):3103-9. PubMed ID: 19383811
[TBL] [Abstract][Full Text] [Related]
18. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal stromal tumors: clinical significance of p53 expression, MDM2 amplification, and KIT mutation status.
Wallander ML; Layfield LJ; Tripp SR; Schmidt RL
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):308-12. PubMed ID: 23060298
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
